IDEXX Laboratories Promotes Michael Erickson To President And CEO, Effective May 12, 2026, As Jonathan Mazelsky Transitions To Executive Chair

IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXX

0.00

Michael Erickson, PhD, to Succeed Jay Mazelsky as President and CEO; Mazelsky to Serve as Executive Chair of the Board of Directors

IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President and Chief Executive Officer, effective May 12, 2026, at which time Jonathan (Jay) Mazelsky, President and CEO, will transition to the role of Executive Chair of IDEXX's Board of Directors (the "Board"). Mr. Mazelsky has announced his intention to retire from the Company immediately following the Company's annual meeting of shareholders in May 2027, and will work closely with Dr. Erickson throughout this extended period to support a seamless transition. Dr. Erickson will also join the Board, effective upon his assumption of the role of President and CEO.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.